The Ductal Carcinoma drugs in development market research report provides comprehensive information on the therapeutics under development for Ductal Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Ductal Carcinoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Ductal Carcinoma and features dormant and discontinued products.
GlobalData tracks 15 drugs in development for Ductal Carcinoma by 12 companies/universities/institutes. The top development phase for Ductal Carcinoma is phase ii with eight drugs in that stage. The Ductal Carcinoma pipeline has 13 drugs in development by companies and two by universities/ institutes. Some of the companies in the Ductal Carcinoma pipeline products market are: Pfizer, Pharma Mar and Marker Therapeutics.
The key targets in the Ductal Carcinoma pipeline products market include Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2.7.10.1), Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2.7.10.1), and Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22).
The key mechanisms of action in the Ductal Carcinoma pipeline product include Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2 with two drugs in Phase III. The Ductal Carcinoma pipeline products include seven routes of administration with the top ROA being Oral and five key molecule types in the Ductal Carcinoma pipeline products market including Small Molecule, and Subunit Vaccine.
Ductal Carcinoma overview
Ductal Carcinoma is early stage of breast cancer where the ductal cells of the breast tissue tend to multiply or grow uncontrollably without any evidence of metastatic. If not treated in initial stages, this could be invasive. Ductal carcinoma is represented in 4 different stages, pre invasive, non-invasive, ductal intraepithelial neoplasia, intra ductal cancer. In invasive form spread of cancer cells into surrounding tissues is observed. Cause is unknown but mutations in BRCA1 and BRCA2 are believed to be one such cause. Other risk factors are family history, age, HRT, oral contraceptives, alcohol. Mammography is the radiographic method to diagnose ductal carcinoma where screening of breasts is done and tissue biopsy. In most cases it is asymptomatic but, in a few cases, the patients are presented with lump or swelling, pain, and a rash on the nipple. Surgery is the primary option of treatment. Either ductal cells that are cancerous are removed or the whole breast if complications of metastatic or in early stages endocrine therapy.
For a complete picture of Ductal Carcinoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
